

Circulating tumor DNA is readily detectable among Ghanaian breast cancer patients supporting non-invasive cancer genomic studies in Africa

Samuel Terkper Ahuno^{1,2}, Anna-Lisa Doebley^{3,4}, Thomas U. Ahearn⁵, Joel Yarney⁶, Nicholas Titiloye⁷, Nancy Hamel⁸, Ernest Adjei⁷, Joe-Nat Clegg- Lamptey⁶, Lawrence Edusei⁶, Baffour Awuah⁷, Xiaoyu Song^{8,9}, Verne Vanderpuye⁶, Mustapha Abubakar⁵, Maire Duggan¹¹, Daniel Stover^{12,13}, Kofi Nyarko¹⁴, John M S Bartlet¹⁵, Francis Aitpillah⁷, Daniel Ansong¹⁶, Kevin L Gardner¹⁷, Felix Andy Boateng⁷, Anne M. Bowcock^{2,10,18,19}, Carlos Caldas²⁰, William D. Foulkes^{8,21,22}, Seth Wiafe²³, Beatrice Wiafe-Addai²⁴, Montserrat Garcia-Closas⁵, Alexander Kwarteng^{1,25}, Gavin Ha^{4*^}, Jonine D. Figueroa^{5,26*^}, Paz Polak^{2,10,17*^}, on behalf of the Ghana Breast Health Study Team

¹Department of Biochemistry and Biotechnology, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

²Departments of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York City, New York

³Molecular and Cellular Biology Program, University of Washington, Seattle, Washington, United States of America

⁴Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

⁵Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD

⁶Korle Bu Teaching Hospital, Accra, Ghana

⁷Komfo Anokye Teaching Hospital, Kumasi, Ghana

⁸Research Institute of the McGill University Health Centre, Montréal, QC, Canada.

⁹Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

¹⁰Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

¹¹Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada

¹²Stefanie Spielman Comprehensive Breast Cancer, The Ohio State University, Columbus, OH, USA

¹³Division of Medical Oncology, Comprehensive Cancer Center, The Ohio State University Medical Center, Columbus, OH, USA

¹⁴University of Ghana, Accra, Ghana

¹⁵Ontario Institute for Cancer Research, Toronto, Ontario, Canada

¹⁶Department of Child Health, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana

¹⁷Department of Pathology and Cell Biology, Columbia University Medical Center, New York, NY 10027, USA

¹⁸Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York City, New York

¹⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York City, New York

²⁰Cancer Research UK Cambridge Centre, Cambridge, UK

²¹Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montréal, QC, Canada.

²²Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montréal, QC, Canada

²³Loma Linda University, School of Public Health, Loma Linda, CA

²⁴Peace and Love Hospital, Kumasi, Ghana

²⁵Kumasi Center for Collaborative Research in Tropical Medicine (KCCR), Kumasi, Ghana

²⁶Usher Institute and CRUK Edinburgh Centre, University of Edinburgh, Edinburgh, United Kingdom

*equal contribution

^corresponding authors: gha@fredhutch.org, Jonine.figueroa@ed.ac.uk, paz.polak@mssm.edu

ABSTRACT:

Circulating tumor DNA (ctDNA) sequencing studies could provide novel insights into the molecular pathology of cancer in sub-Saharan Africa. ctDNA was readily detected in 15 blood samples collected in Ghana at the time of suspected breast cancer. Genomic alterations previously associated with unfavorable prognostic outcomes were observed in the majority of patients. This supports the use of liquid biopsies for diagnosis, surveillance and clinical management of breast cancer in Ghana.

It is well documented that there is a need to increase diversity in genomic research, particularly in African populations, where more aggressive early onset breast cancers are diagnosed, and where non-invasive methods could provide novel insights for cancer prevention and treatment. This would have both regional and global impact. Breast cancer incidence is rising in Africa and fast becoming the most common cancer on the continent where it accounts for 60% of global breast cancer deaths¹. Technological advances in genomic and bioinformatic analysis of blood-based biomarkers offer opportunities for translational molecular oncology studies in Africa that could inform clinical-decision-making, including precision medicine treatments and new paradigms for prevention, surveillance, diagnosis and clinical management of cancer.

Whole genome sequencing of cell-free DNA (WGS-cfDNA) can identify mutations from tumor cells that shed their DNA into the bloodstream in the form of circulating tumor DNA (ctDNA)²⁻⁴. ctDNA studies have been investigated in mostly European ancestry populations for possible relevance of cancer diagnosis, screening, early detection, tumor classification, and monitoring responsiveness to treatments. However, with increased investments in emerging technologies and bioinformatics, similar such studies could facilitate a quantum leap forward for molecular oncology and precision medicine in Africa⁵⁻⁷. To establish proof of concept, we used samples from Ghana, where organized mammography screening programs are lacking and late presentation is common, with the majority (62%) of breast cancer patients diagnosed with tumors >5cm⁸. Knowledge about the genomic landscape of tumors among women in Africa is limited; therefore, we tested whether ctDNA is readily detectable in Ghanaian breast cancer patients. We hypothesized that WGS-cfDNA in African women with breast cancer could reveal somatic alterations⁹ of potential clinical relevance and provide new genomic insights.

We selected 15 breast cancer patients with duplicate plasma samples collected from the Ghana Breast Health Study (GBHS)⁹. The GBHS is a population-based case-control study which recruited over 1200 incident breast cancer cases and collected samples at the time cancer was suspected. Cases were recruited from 2013-2015 from three hospital sites in the cities of Accra and Kumasi, Ghana. Demographics and tumor characteristics were similar to the overall patient population, with a median age at diagnosis of 49.5 (IQR 44.3-57.8) years. Nine patients (60%) presenting with tumors larger than 5cm, and the remaining presenting with tumors 2 to 5cm¹⁰. Nine (75%) of 12 patients with pathologic grade data were poorly differentiated. For three (3, 20%) patients, grade information was not available, and no tumor was classified as well-differentiated. Stage of breast cancer was not available; however, it is well documented that these patients are more frequently diagnosed with tumors with more advanced disease¹⁰.

Immunohistochemical (IHC) staining was available for the majority of patients and was used to classify proxies of molecular subtypes (Figure 1): Luminal A (ER+/PR+/HER2-, n=6, 40%), Luminal B (ER+ and or/PR+/HER2+, n=2, 13%), HER2-enriched (ER-/PR-/HER2+, n=2, 13%) and triple negative breast cancer (TNBC)/basal (ER-/PR-/HER2-, n=4, 27%)¹¹ and indeterminate (ER missing/PR-/HER2-, n=1, 7%). cfDNA extraction and WGS at both 30x (high depth) and 0.1x (low depth) was conducted by the Broad Institute Genomic Services. The ichorCNA¹² software was used on Next Generation Sequencing (NGS) read counts to determine the ctDNA fraction of total cfDNA and copy number alteration profiles (see Supplementary Methods for more details).

The 30x WGS-cfDNA analysis indicated that all 15 breast cancer patients had at least 1% of the total cfDNA corresponded to ctDNA (median [IQR] 3.96% [2.22%-8.13%]). The tumor fractions in TNBC samples were significantly higher than the other subtypes ($p=0.04$; two-sided Wilcoxon rank sum test). A comparison of the estimated ctDNA fraction from the 30x cfDNA-WGS with the 0.1x WGS-cfDNA showed high concordance between estimated ctDNA fractions (Pearson $r = 0.9$). Using 0.1x WGS-cfDNA, a minimum of 1% ctDNA fraction was detected in 12 (80%) (95% CI 52%-96%, Figure 1).



Figure 1. Co-mutation plot showing association between clinical information and genomic characteristics. Patients are represented by the columns ordered by decreasing ctDNA fraction. The top two rows show bar plots of tumor fractions estimated with ichorCNA from cfDNA sequenced with 30x WGS-cfDNA (gold bars) and 0.1x WGS-cfDNA (blue bars) ($n=15$ patients). The horizontal line across the bar plot shows the limit of detection of ichorCNA for 0.1x (ctDNA fraction= 3%) and a threshold for 30x (ctDNA fraction=1%) for the detection of ctDNA. Immunohistochemical stains for ER, PR and HER2+, age and tumor size classification are presented. Copy number gain and loss of selected genes exhibiting a high frequency of deletion or amplification in breast cancers from TCGA¹³ are shown in the bottom panel. Genes with the caret symbol (^) and shaded show copy number alterations that are significantly higher among breast cancers of African-Ancestry than in European-Ancestry patients¹³.

Copy number profiling showed extensive amplification and deletion of multiple chromosomal regions (Figure 2 and Supplementary Figure 1) including those with oncogenes and tumor suppressor genes associated with breast cancer (Figure 1)¹³. We observed a high frequency (>50%) of copy number gain in three out of the five regions and potential target genes for the amplification (chr8p11-12 [ZNF703] $n=8$, 53.3%; chr8q24.2 [MYC] $n=9$, 60%; chr19q12 [CCNE1] $n=9$, 60%),

which were previously reported to be amplified at higher frequency in patients of African-American (AA) ancestry compared to those of European-American (EA) origin in TCGA datasets¹³. Chr8p11-12 amplification is increased more than two-fold in breast tumors of AA compared to EA patients¹³ and we observed high-level amplification (more than four copies) of chr8p11-12 in four (27%, 95% CI 8%-55%) Ghanaian samples. Eight patients (53%, 95% CI 27%-79%) showed gain of at least one copy of this region that contains oncogenes ZNF703 and FGFR1 (Figure 2).




Figure 2: Genome-wide copy number profiles of 4 patients from cfDNA sequenced at 30x WGS. The x-axis represents chromosomes (chr1-22:X) and y-axis shows log₂ copy number. Blue represents copy neutral, i.e. chromosomal loci with standard 2 copies (such as chr3, chr4, & chr5 in P07). Deletions of genomic loci (ie. chr4p in P01 & P08) are shown in green. Gains (3-4 copies) and amplifications (>4 copies) of chromosomal loci (such as chr8p12 containing ZNF703 genes in P01, P07, P08 & P15) are shown in brown and red colors, respectively. P08 has amplification of the chr17 locus containing ERBB2. Arrows indicate the gene and estimated copy number (CN) of the predicted segment by ichorCNA. GU- Grade Unknown, G2- moderately differentiated, G3- poorly differentiated, WGS- whole genome sequencing, CN-copy number, ER- estrogen receptor, PR-progesterone receptor, HER2 – human epidermal growth factor receptor 2, ctDNA-circulating-tumor DNA.

Local amplification of chr8p11-12 has been associated with luminal B tumors^{14,15} late recurrence¹⁶ in women of European ancestry. The amplification is associated with worse outcome than patients with no change in copy number even after adjustment of stage, grade and cancer subtype¹⁷. In our study, the tumors of patients with high amplification of chr8p11-12 regions were observed

across the different IHC defined molecular subtypes of breast cancer. Data support ZNF703 as a driver gene that is hypothesized to be relevant in the etiology of breast cancer through regulation of both mammary basal and luminal progenitors¹⁵. ZNF703 amplification leads to increase in ZNF703 expression levels, which have been associated with decrease in overall survival for ER positive and luminal B patients¹⁸. Other potential drivers from chr8p11-12 include FGFR1 amplification within the chr8p11-12 region, which has been associated with worse outcomes in luminal A breast cancers¹⁴ as well as resistance to endocrine therapy¹⁹.

Another common high-level amplification event in our Ghana patient samples was at chr8q24, a region that contains MYC. Nine patients (60%) had at least gain (CN \geq 3) of chromosomal locus chr8q24 which contains MYC. This amplification is also enriched in AA¹³ and has been linked to poor prognosis²⁰. An increase in copy number was reported in 70-80% of TNBC patients²¹ and our data was consistent with this, as we observed three (75%) of four TNBC patients in our series harboring high-level amplification of this region.

Interestingly, all patients with levels of ctDNA higher than >10% were TNBC cases (3 of 3), and showed similar copy number patterns to TNBC diagnosed among patients of European ancestry²². These included loci harboring the two telomerase genes TERC and TERT, implicating upregulation of telomerase activity in breast oncogenesis²³.

Lastly, of the four patients classified as HER2+ based on IHC, two had increased in copy number regions that included ERBB2 (50 and 3 copies for patients P06 and P08 respectively), consistent with data showing classification of HER2 status was variable for different quantitative assays²⁴.

Our study shows the depth of genomic information that can be obtained by interrogating WGS-cfDNA from plasma samples of breast cancer patients in Ghana. This can reveal copy number alterations and provide more detailed genomic insights into breast cancer in this and other populations with limited resources. Our observation of key alterations having similar frequencies in Ghanaian and AA breast cancer patients suggests that ctDNA may be a useful method for comparative genomic studies of breast cancer as well as for other cancers. In particular targeted assays for the detection of high copy number of ZNF703/FGFR1 and MYC would increase the sensitivity of their detection in the low fractions of ctDNA circulating in the blood. As this amplification is established to be associated with late stage tumors¹⁷, future research is needed to determine factors associated with its higher frequency, and in particular whether it is due to presentation at a late cancer stage or is present due to other genetic, environmental or lifestyle associated factors.

On the African continent, cancer incidence is rising, mortality rates are high and access to molecular pathology is limited. Non-invasive methods for molecular tumor subtyping could be transformative. The rapid advancement of sequencing technologies and the estimated ctDNA fraction levels (>1%) in this sample of Ghanaian patients in this study indicate that the exploration of alternative methods such as methylation-based cfMedip-seq and panel testing are warranted. These could have high sensitivity (for at least 0.1% ctDNA fraction) and be suitable for patients at the time of diagnosis^{2,4,12}. Moreover, the ability to detect tumor with 0.1x WGS-cfDNA support additional advances for sample collection methods (such as a finger prick blood test²⁵). New long read sequencing technologies (such as Nanopore sequencing) would allow more facile translation

of cancer genomic data to be used at the point of care. Hence, our study shows that an analysis of ctDNA could be a tool for future molecular oncology studies in Africa that merits further investment for cancer etiology, surveillance, molecular oncology and clinical trial studies that are urgently needed to improve cancer survival in Africa.

Acknowledgement

The authors would like to thank the patients for donating samples to the GBHS study. We would also like to thank Jonathan B Reichel (University of Washington) for helpful comments in preparation of the manuscript. This study was supported in part by a Komen Leadership award to WDF (SAC110008). GH is supported by NCI K22 CA237746. PP is supported by the Jimmy V foundation scholar award. JDF acknowledges personal funding on molecular subtypes of breast cancer from the Wellcome Trust (207800/Z/17/Z) and MRC (MR/S015027/1).

The authors acknowledge the research contributions of the Cancer Genomics Research Laboratory for their expertise, execution, and support of this research in the areas of project planning, wet laboratory processing of specimens. This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, under NCI Contract No. 75N910D00024. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

Author contribution

Conception and design of the study: P.P, W.D.F, J.D.F. and G.H. The main bioinformatic and computational analysis: S.T.A. Assisting in the computational work: A.L.D, G.H., and P.P. Data and sample collection: L.E, N.T, E.A, J.N.C.L, J.Y, B.W.A, B.A, V.V, M.D, S.W, K.N, F.A, D.A and Ghana Breast Health Study team. Sample selection and phenotype data: T.U.H. and M.G.C. Pathology review: L.E., N.T., E.A., M.D. Statistical analysis: S.T.A, P.P, G.H., X.S, and J.D.F. Interpretation of data: all authors. Drafting of the paper: S.T.A, P.P, W.D.F, J.D.F., N.H. and G.H. Revised work and provided important intellectual content: all authors. Final approval of the paper: all authors. P.P, G.H. and J.D.F. equally supervised this work.

Ghana Breast Health Study team

Ghana Statistical Service, Accra, Ghana: Dr Robertson Adjei and Dr Lucy Afriyie. Korle Bu Teaching Hospital, Accra, Ghana: Professor Dr Anthony Adjei, Dr Florence Dedey, Victoria Okyne, Naomi Ohene Oti, Evelyn Tay (deceased), Dr Adu-Aryee, Angela Kenu and Obed Ekpedzor. Komfo Anoyke Teaching Hospital, Kumasi, Ghana: Marion Alcpaloo, Isaac Boakye, Bernard Arhin, Emmanuel Assimah, Samuel Ka-chungu, Dr Joseph Oppong and Dr Ernest Osei-Bonsu. Peace and Love Hospital, Kumasi, Ghana: Prof Margaret Frempong, Emma Brew Abaidoo, Bridget Nortey Mensah, Samuel Amanama, Prince Agyapong, Debora Boateng, Ansong Thomas Agyei, Richard Opoku and Kofi Owusu Gyimah. New York-Presbyterian/Weill Cornell Medical Center, NY, USA: Dr Lisa Newman. National Cancer Institute, Bethesda, MD, USA: Louise A. Brinton, Maya Palakal and Jake Thistle. Westat, Inc.: Michelle Brotzman, Shelley Niwa, Usha Singh and Ann Truelove. University of Ghana: Prof Richard Biritwum.

Conflict of interest disclosure:

GH: Patent application (US16/084,890; Broad Institute). JMSB reports consultancies from Insight Genetics, Inc., BioNTech AG, Biotheranostics, Inc., Pfizer, Rna Diagnostics Inc., oncoXchange/MedcomXchange Communications Inc, Herbert Smith French Solicitors, Oncocyte Corporation, honoraria from NanoString Technologies, Inc, Oncology Education, Biotheranostics, Inc., MedcomXchange Communications Inc, research funding from Thermo Fisher Scientific, Genoptix, Agendia, NanoString Technologies, Inc., Stratifyer GmbH, Biotheranostics, Inc., travel and accommodations expenses from Biotheranostics, Inc., NanoString Technologies, Inc., Breast Cancer Society of Canada, Scientific Advisory Board participation from MedcomXchange Communications Inc.

Ethical approval:

The study was approved by the Special Studies Institutional Review Board of the National Cancer Institute (Rockville, MD), the Ghana Health Service Ethical Review Committee and institutional review boards at the Noguchi Memorial Institute for Medical Research (Accra, Ghana), the Kwame Nkrumah University of Science and Technology (Kumasi, Ghana), the School of Medical Sciences at Komfo Anokye Teaching Hospital (Kumasi, Ghana) and Westat (Rockville, MD). All participants provided written informed consent.

Data Availability

Raw sequencing data will be deposit in dbGaP and can be used for breast cancer research and other adult disease only.

Code availability

Code for ichorCNA v0.2.0 used to analyze 0.1x WGS-cfDNA data can be accessed at <https://github.com/broadinstitute/ichorCNA>. Analysis of 30x WGS-cfDNA data used an updated version of ichorCNA and can be accessed at <https://github.com/GavinHaLab/ichorCNA> [commit b2bbce0, June 22, 2020].

References

- 1 Bray, F. *et al.* Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* **68**, 394-424, doi:10.3322/caac.21492 (2018).
- 2 Cohen, J. D. *et al.* Detection and localization of surgically resectable cancers with a multi-analyte blood test. *Science* **359**, 926-930, doi:10.1126/science.aar3247 (2018).
- 3 Lennon, A. M. *et al.* Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention. *Science*, doi:10.1126/science.abb9601 (2020).
- 4 Liu, M. C. *et al.* Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. *Annals of Oncology*, doi:10.1016/j.annonc.2020.02.011.
- 5 Consortium, H. A. *et al.* Research capacity. Enabling the genomic revolution in Africa. *Science (New York, N.Y.)* **344**, 1346-1348, doi:10.1126/science.1251546 (2014).

- 6 Temilola, D. O. *et al.* The Prospect and Challenges to the Flow of Liquid Biopsy in Africa. *Cells* **8**, doi:10.3390/cells8080862 (2019).
- 7 Arko-Boham, B. *et al.* Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers. *Cancer Genet* **235-236**, 65-71, doi:10.1016/j.cancergen.2019.04.062 (2019).
- 8 Brinton, L. *et al.* Factors contributing to delays in diagnosis of breast cancers in Ghana, West Africa. *Breast Cancer Res Treat* **162**, 105-114, doi:10.1007/s10549-016-4088-1 (2017).
- 9 Brinton, L. A. *et al.* Design considerations for identifying breast cancer risk factors in a population-based study in Africa. *Int J Cancer* **140**, 2667-2677, doi:10.1002/ijc.30688 (2017).
- 10 Figueroa, J. D. *et al.* Reproductive factors and risk of breast cancer by tumor subtypes among Ghanaian women: A population-based case-control study. *Int J Cancer* **147**, 1535-1547, doi:10.1002/ijc.32929 (2020).
- 11 Brien, K. M. *et al.* Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study. *Clinical Cancer Research* **16**, 6100, doi:10.1158/1078-0432.CCR-10-1533 (2010).
- 12 Adalsteinsson, V. A. *et al.* Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. *Nat Commun* **8**, 1324, doi:10.1038/s41467-017-00965-y (2017).
- 13 Huo, D. *et al.* Comparison of Breast Cancer Molecular Features and Survival by African and European Ancestry in The Cancer Genome Atlas. *JAMA Oncol* **3**, 1654-1662, doi:10.1001/jamaoncol.2017.0595 (2017).
- 14 Shi, Y. J. *et al.* FGFR1 is an adverse outcome indicator for luminal A breast cancers. *Oncotarget* **7**, 5063-5073, doi:10.18632/oncotarget.6563 (2016).
- 15 Holland, D. G. *et al.* ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium. *EMBO Mol Med* **3**, 167-180, doi:10.1002/emmm.201100122 (2011).
- 16 Luen, S. J. *et al.* Identifying oncogenic drivers associated with increased risk of late distant recurrence in post-menopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. *Ann Oncol*, doi:10.1016/j.annonc.2020.06.024 (2020).
- 17 Moelans, C. B., van Maldegem, C. M. G., van der Wall, E. & van Diest, P. J. Copy number changes at 8p11-12 predict adverse clinical outcome and chemo- and radiotherapy response in breast cancer. *Oncotarget* **9** (2018).
- 18 Reynisdottir, I. *et al.* High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer. *Cancer Med* **2**, 437-446, doi:10.1002/cam4.88 (2013).
- 19 Turner, N. *et al.* FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. *Cancer research* **70**, 2085-2094, doi:10.1158/0008-5472.CAN-09-3746 (2010).
- 20 Xu, J., Chen, Y. & Olopade, O. I. MYC and Breast Cancer. *Genes Cancer* **1**, 629-640, doi:10.1177/1947601910378691 (2010).

- 21 Stover, D. G. *et al.* Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. *J Clin Oncol* **36**, 543-553, doi:10.1200/JCO.2017.76.0033 (2018).
- 22 Curtis, C. *et al.* The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. *Nature* **486**, 346-352, doi:10.1038/nature10983 (2012).
- 23 Cao, Y., Bryan, T. M. & Reddel, R. R. Increased copy number of the TERT and TERC telomerase subunit genes in cancer cells. *Cancer Sci* **99**, 1092-1099, doi:10.1111/j.1349-7006.2008.00815.x (2008).
- 24 Gupta, S. *et al.* Quantitative assessments and clinical outcomes in HER2 equivocal 2018 ASCO/CAP ISH group 4 breast cancer. *npj Breast Cancer* **5**, 28, doi:10.1038/s41523-019-0122-x (2019).
- 25 Heider, K. *et al.* Detection of ctDNA from Dried Blood Spots after DNA Size Selection. *Clin Chem* **66**, 697-705, doi:10.1093/clinchem/hvaa050 (2020).